JP2023549765A - Ｈａ－１抗原を認識する結合タンパク質及びその使用 - Google Patents

Ｈａ－１抗原を認識する結合タンパク質及びその使用 Download PDF

Info

Publication number
JP2023549765A
JP2023549765A JP2023528001A JP2023528001A JP2023549765A JP 2023549765 A JP2023549765 A JP 2023549765A JP 2023528001 A JP2023528001 A JP 2023528001A JP 2023528001 A JP2023528001 A JP 2023528001A JP 2023549765 A JP2023549765 A JP 2023549765A
Authority
JP
Japan
Prior art keywords
cell
cells
tcr
binding protein
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549765A5 (https=
JPWO2022099100A5 (https=
Inventor
ナイヤル リブー
マクビース ギャビン
ジャンガルウェ ソナル
エム ジュレウィッツ モリー
エス バシンスキ アンドリュー
シュー チーカイ
ジェイ ブード アントワン
クラ トマシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tscan Therapeutics Inc
Original Assignee
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc filed Critical Tscan Therapeutics Inc
Publication of JP2023549765A publication Critical patent/JP2023549765A/ja
Publication of JP2023549765A5 publication Critical patent/JP2023549765A5/ja
Publication of JPWO2022099100A5 publication Critical patent/JPWO2022099100A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
JP2023528001A 2020-11-06 2021-11-08 Ｈａ－１抗原を認識する結合タンパク質及びその使用 Pending JP2023549765A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063110851P 2020-11-06 2020-11-06
US63/110,851 2020-11-06
US202063111462P 2020-11-09 2020-11-09
US63/111,462 2020-11-09
US202063129804P 2020-12-23 2020-12-23
US63/129,804 2020-12-23
US202163175350P 2021-04-15 2021-04-15
US63/175,350 2021-04-15
PCT/US2021/058382 WO2022099100A2 (en) 2020-11-06 2021-11-08 Binding proteins recognizing ha-1 antigen and uses thereof

Publications (3)

Publication Number Publication Date
JP2023549765A true JP2023549765A (ja) 2023-11-29
JP2023549765A5 JP2023549765A5 (https=) 2024-11-18
JPWO2022099100A5 JPWO2022099100A5 (https=) 2024-11-18

Family

ID=81458633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528001A Pending JP2023549765A (ja) 2020-11-06 2021-11-08 Ｈａ－１抗原を認識する結合タンパク質及びその使用

Country Status (10)

Country Link
US (1) US20230398217A1 (https=)
EP (1) EP4240490A4 (https=)
JP (1) JP2023549765A (https=)
KR (1) KR20230117576A (https=)
AU (3) AU2021323388C1 (https=)
CA (1) CA3197255A1 (https=)
IL (1) IL302616A (https=)
MX (1) MX2023005179A (https=)
TW (1) TW202227499A (https=)
WO (1) WO2022099100A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4633671A1 (en) * 2022-12-14 2025-10-22 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
AU2025202444A1 (en) * 2024-04-08 2025-10-23 Tscan Therapeutics, Inc. Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds
AU2025202443A1 (en) * 2024-04-08 2025-10-23 Tscan Therapeutics, Inc. Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
WO2025231299A1 (en) * 2024-05-02 2025-11-06 Fred Hutchinson Cancer Center Tcr t cell therapy targeting ha-1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020030631A1 (en) * 2018-08-06 2020-02-13 Medigene Immunotherapies Gmbh Ha-1 specific t cell receptors and their use
WO2020076156A1 (en) * 2018-10-10 2020-04-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Binding proteins specific for ha-1h and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390011A1 (ru) * 2010-07-28 2013-07-30 Иммьюнокор Лтд. Т-клеточные рецепторы
CA3035075A1 (en) * 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020030631A1 (en) * 2018-08-06 2020-02-13 Medigene Immunotherapies Gmbh Ha-1 specific t cell receptors and their use
WO2020076156A1 (en) * 2018-10-10 2020-04-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Binding proteins specific for ha-1h and uses thereof

Also Published As

Publication number Publication date
EP4240490A4 (en) 2025-06-18
MX2023005179A (es) 2023-07-13
EP4240490A2 (en) 2023-09-13
AU2021323388B2 (en) 2022-07-28
TW202227499A (zh) 2022-07-16
CA3197255A1 (en) 2022-05-12
KR20230117576A (ko) 2023-08-08
WO2022099100A2 (en) 2022-05-12
US20230398217A1 (en) 2023-12-14
WO2022099100A3 (en) 2022-06-16
AU2022241563A1 (en) 2022-11-03
AU2026200575A1 (en) 2026-02-19
IL302616A (en) 2023-07-01
AU2021323388C1 (en) 2022-10-27
AU2021323388A1 (en) 2022-05-26
AU2022241563B2 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
US20240197877A1 (en) Binding proteins recognizing ha-2 antigen and uses thereof
AU2022241563B2 (en) Binding proteins recognizing HA-1 antigen and uses thereof
US20230270832A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
US20230272049A1 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
US20240190931A1 (en) Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
US20250249039A1 (en) Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
CN116940593A (zh) 识别ha-1抗原的结合蛋白及其用途
CN118103049A (zh) 识别ha-2抗原的结合蛋白及其用途
JPWO2023086477A5 (https=)
KR20250099771A (ko) Magea1 면역원성 펩타이드, magea1 면역원성 펩타이드를 인식하는 결합 단백질 및 이의 용도
TW202547854A (zh) Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途
CN118510797A (zh) 识别hpv16 e7抗原的结合蛋白和其用途
CN118613497A (zh) Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306